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ABSTRACT  
 
Influenza virus hemagglutinin (HA) envelope protein aids in the recognition and 
attachment of the virion to host cell receptors.  HA residues important for infection of the H5N1 
type virus, an especially virulent type, are different than those previously characterized for other 
HA types.  This project used mutagenesis to help identify H5 HA domains responsible for 
function.  Of the 70 mutants tested, 25 showed infectivity levels similar to the WT, 24 showed no 
infectivity, 18 showed decreased infectivity, and 3 showed increased infectivity.  
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BACKGROUND 
 
 
Introduction 
 
Influenza, commonly referred to as the flu, is an acute respiratory disease that results 
from infection by influenza viruses. Cases of influenza can range from mild to severe, and can 
potentially lead to death. Influenza viruses are typically transmitted from person to person 
through air droplets generated by coughing, sneezing, or simply talking. According to the Center 
for Disease Control and Prevention, 5-20% of the United States population is infected with a 
seasonal influenza strain annually, causing 3,000 to 49,000 fatalities. Influenza strongly affects 
small children, elderly people, and those with weakened immune systems more severely than 
others (CDC.gov, 2010b).  Only types A and B cause the seasonal epidemics in humans, while 
type C typically causes mild respiratory illness (Skehel, 2009).  The incubation period for 
influenza is approximately 1-7 days, and people can be contagious one day prior to experiencing 
symptoms until about seven days after symptoms appear.  Symptoms may include fever, cough, 
sore throat, runny nose, muscle aches, headaches, fatigue, vomiting, and diarrhea.  Although 
most people recover from influenza in about two weeks, some develop life-threatening 
conditions such a pneumonia, bronchitis, and sinus and ear infections (CDC.gov, 2011b). 
Influenza undergoes antigenic drift and shift to cause epidemics and pandemics. 
Antigenic drift refers to small changes in the virus that occur continually over time. Antigenic 
shift is a major change in the virus and typically, results in a worldwide pandemic (CDC.gov, 
2011b).  This is because it generates a new strain to which the population has no immunity. 
Several influenza pandemics have been documented throughout human history; however, the 
1918 Spanish Flu resulted in the most deaths.  In 1918, type A H1N1 influenza infected 
approximately one third of the world’s population, and killed at least 50 million people 
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Figure-1: Diagram of  Influenza-A Virion 
General Structure.  The RNA virus is 
enveloped, and contains a segmented genome. 
Two surface glycoproteins, HA and NA, and 
the M2 ion-channel protein are embedded in 
the viral envelope, which is derived from the 
host plasma membrane (Horimoto and 
Kawaoka, 2005) 
(Taubenberger and Morens, 2006). Other pandemics have occurred since the 1918 Spanish Flu, 
including the 1957 Asian Influenza (H2N2), the 1968 Hong Kong Influenza (H3N2), the 1977 
Russian Influenza (H1N1), and most recently the 2009 “swine flu” (H1N1) (Horimoto and 
Kawaoka, 2005; Tang et al., 2011). 
 
Influenza Virus 
Influenza belongs to the Orthomyxovirus family and are negative-sense, single-stranded 
RNA viruses (Couch, 1996).  The virus particle consists of an outer lipid envelope containing 
hemagglutinin (HA) and neuraminidase (NA) (Figure 1), which are knob-shaped glycoproteins 
between 80 and 120 nm in diameter and 200-300 nm in length. The surface glycoproteins, HA 
and NA, and the M2 ion-channel protein are all embedded in the viral envelope. The genome of 
influenza viruses is linear and segmented, and type A consists of 8 segments (Figure 1) 
(Horimoto and Kawaoka, 2005; Kawaoka et al., 2006). 
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Nomenclature 
Antigenic differences in their nucleoprotein (NP) and matrix protein (M) allow influenza 
viruses to be classified as types A, B, and C. Influenza A is the most virulent type and is further 
divided into different subtypes based on the antigenicity of the HA and NA surface glycoprotein. 
Currently 16 HA (H1-H16) and 9 NA (N1-N9) have been identified.  The HA subtypes are 
differentiated by their reactivity with subtype-specific hyper-immune sera, while the NA 
subtypes differ in structure and sensitivity to antiviral drugs (Skehel, 2009). Currently, influenza 
A subtypes H1N1 and H3N2 are found to infect humans.  Influenza type B viruses are not 
divided into subtypes, however, they can still be divided into different strains. Influenza A virus 
is clinically the most important of the influenza viruses because it is responsible for all the recent 
pandemics. In addition, since influenza A and B cause epidemics in humans, they are both 
included in annual vaccines (CDC.gov, 2011b).  
 
Morphology of the Genome and Replication 
Influenza virus infects the upper respiratory tract of the host, and mainly targets the 
columnar epithelial cells. The virus binds to the receptors through hemagglutinin (HA), and 
enters the cell by receptor-mediated endocytosis (Figure 2). The acidic pH of the endocytic 
vesicles induces the viral HA to undergo a conformation change from the nonfusogenic to the 
fusogenic form of the protein (Behrens and Stoll, n.d.). Following fusion of the viral envelope 
with the endosome, the viral genome is released into the nucleus. Viral RNP complex dissociates 
from the M1 protein and is imported to the host nucleus for transcription and translation. The 
progeny viruses are released from the host cell by budding. Budding is a process by which 
enveloped viruses detach from a cell by exocytosis in a pinching-off manner (Chazal and Gerlier, 
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Figure-2: Diagram of  Influenza-A Viral 
Replication.  The virion attaches to the surface 
of cells via the binding of HA to sialic acid 
residues in surface proteins, and enters 
endocytic vesicles (upper diagram).  
Acidification of the vesicle results in viral RNA 
release into the nucleus (diagram center left) for 
transcription and translation.  Mature virions 
exit the cell via exocytosis.  (Behrens and Stoll, 
n.d.) 
2003). The neuraminidase (NA) activity of NA then cleaves the HA bound to sialic acid residues 
on the cellular surface that would otherwise retain the new virus at the cell surface. Localized 
infections typically occur because most influenza strains possess HAs that are only cleaved by 
proteases from the upper respiratory tract.  However, systemic infections occur when viral strains 
have more universal cleavage sites compared to seasonal or less pathogenic viruses (Garten and 
Klenk, 1999). 
 
 
 
Current Treatments 
 
Vaccines 
 
 Since the influenza virus is constantly undergoing antigenic drift, the annual seasonal 
influenza vaccine is continually modified. Three different types of influenza shots are available, 
however the most common influenza vaccine consists of inactive heat killed virus administered 
through a needle into the upper arm. According to the Center for Disease Control and 
Prevention, this form of vaccination is approved for people 6 months or older. This seasonal 
vaccine consists of three different influenza viral strains that scientists determine to be the 
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greatest risk in that year. For the current 2011-2012 season it includes two type A and one type B 
strains. The vaccine provides antigens to the body which stimulate the formation of protective 
antibodies against the virus (CDC.gov, 2011a).   
 A nasal-spray influenza vaccine (FluMist®) has also been approved for individuals 
between the ages of 2 and 49 who are not pregnant. This vaccine is made of attenuated, live 
influenza virus that is administered as a nasal spray. The virus is “cold-adapted” which means 
that it will only cause infection in the cooler temperatures found within the nose. The virus will 
not infect the lungs or other parts of the body where warmer temperatures exist (CDC.gov, 
2011a).  
 
Antiviral Treatments 
 
 Since the nature of pandemic influenza strains cannot be predicted, a vaccine against 
them cannot be developed. Antivirals are the first line of defense against a new influenza 
pandemic strain. They are also required for immune-compromised people who are non-
responders or weak responders to the vaccine. The FDA-approved antivirals target either NA or 
M proteins. The FDA approved antiviral, Oseltamivir (commonly referred to as Tamiflu) is a 
neuraminidase inhibitor used to treat and prevent influenza A and B viruses in patients one year 
of age and older (Treanor et al., 2000; CDC.gov, 2009).  Oseltamivir also decreases the risk of 
secondary complications including otitis media, bronchitis, pneumonia, and sinusitis (Gillissen 
and Hoffken, 2002). It is used both prophylactically and therapeutically. The antiviral is usually 
given orally to individuals who have experienced symptoms for less than two days as it is only 
effective during the viral replication phase when the neuraminidase is used to release viral 
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particles (Gillissen and Hoffken, 2002; NIH.gov, 2011). More recently, the majority of 
circulating influenza strains are resistant to Oseltamivir treatment. 
 Zanamivir is another FDA approved antiviral used to treat and prevent influenza A and B 
infections. This antiviral is a sialic acid analogue and a neuraminidase inhibitor (Hayden et al., 
1997).  Zanamivir is approved to treat infections in people seven years of age and older, and is 
approved to prevent infections in people five years of age and older (CDC.gov, 2009).  This 
antiviral is administered orally or through inhalation (Treanor et al., 2000).  
 Amantadine and rimantadine are antivirals used to treat and prevent influenza A 
infections only. Amantadine is used in patients older than one year, and rimantadine is used to 
treat people older than thirteen years, and to prevent influenza in people older than one year 
(CDC.gov, 2009).  These antivirals have no activity against influenza B strains, and can cause 
undesirable central nervous system and gastrointestinal side effects.  Amantadine and 
rimantadine are both associated with the appearance of resistant influenza virus strains in treated 
patients (Treanor et al., 2000). Currently they are not used since most influenza strains are 
resistant to the two antivirals. 
 
Pseudotype Viruses 
 Pseudotype virus has the backbone of one virus and the envelope proteins of another 
virus. They are widely used as surrogate models to study viral entry for high pathogenic viruses 
that required a BSL-3/4 facility, or for viruses that are difficult to generate. By using pseudotype 
viruses, the viral entry of these viruses can be studied in a BSL-2 facility. During this MQP 
project, the human immunodeficiency virus backbone was used to generate influenza pseudotype 
virus. Other viruses such as vesicular stomatitis virus and murine leukemia virus are also widely 
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Figure-3: Diagram of 
Phenotypic Mixing to 
Produce Pseudotype Virus 
(Murray et al., 2010).   
used to generate pseudotype viruses. Since viral entry is solely determined by the interactions of 
its envelope glycoproteins and cellular receptors, the pseudotype virus behaves like influenza; 
however, it does not contain the envelope protein genes. Since the genes are not present, the 
pseudotype virus is only able to go through one cycle of replication and cannot produce progeny 
HIV virus (Figure 3). This system allows easy genetic manipulation, with the safety concerns 
alleviated. 
 
 
 
Hemagglutinin Structure 
 Hemagglutinin (HA) is a glycoprotein that plays an essential role in viral infection of 
host cells. The envelope HA spikes are transmembrane glycoproteins that are associated with the 
M1 protein at the inner surface of the membrane. Cleavage of HA by cellular proteases is 
required to expose the HA fusion peptide that is responsible for the fusion between the viral 
envelope and the endosomal membrane (Gamblin and Skehel, 2010). 
Influenza virus hemagglutinin (HA) is responsible for binding the virus to host cell 
receptors, enabling infection.  Due to this key role in infection, HA has been used as a target for 
HIV 
Flu 
HIV 
core 
Flu 
core 
HA & NA GP 120 
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Figure-4: Crystalline Structure of Viet04 HA. 
Each monomer is shown in a different color, and 
carbohydrates are shown in orange (Stevens et al., 
2006) 
drug and vaccine development. Each monomer is synthesized as a single polypeptide chain 
(HA0).  Following the binding of the virion to the cell surface, the cleavage of HA0 into HA1 and 
HA2 is essential for HA activity. HA1 mediates viral attachment to sialic acid on the host cell, 
while HA2 mediates endosomal membrane fusion. HA is composed of a globular head containing 
the receptor-binding domain and alpha-helical stalks containing the HA1/HA2 cleavage site. All 
HA types have conserved receptor-binding domains, and the binding site is made up of three 
structural elements, essentially an alpha-helix and two loops. Figure 4 shows the crystalline 
structure of Influenza strain Viet04 H5N1 HA (Stevens et al., 2006).   
 
 
 
Mutational Studies of Influenza HA 
Multiple mutational studies of this influenza HA protein have previously been performed 
for the purpose of identifying key amino acid residues important in viral function. Most of these 
studies, however, are focused mutations or are performed in HA from non H5 subtypes. In one of 
these studies, point mutations were made within the H5N1 hemagglutinin protein to determine 
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the role of individual amino acids in controlling the fusion acidity (Reed et al., 2009). The 
locations of eight key residues involved in pH control were identified by mutagenizing H5N1 
HA2 coiled-coil residues that altered the pH in H3 and H7 HA proteins. Eleven other residues 
were also identified by sequence alignment of HA proteins from different subtypes.  Seven of the 
mutations created were found to alter the pH, six of which were located in the fusion peptide 
pocket.  Based on this Reed et al. (2009) study, it seems that fusion peptide pocket residues may 
commonly regulate HA acid stability across all HA subtypes (Reed et al., 2009).   
 Another HA mutagenesis study was performed by Su et al. (2008), and used pseudo-
typed HIV-HA-luc viruses encoding mutated HA’s to study the effects of HA mutations on 
infection (Su et al., 2008).  The entry of HA mutants into live mammalian cells was measured by 
the amount of luciferase expression and compared with the sialic acid receptors on the cells. 
Typically, human influenza strains prefer to bind to terminal sialic acids with an α2,6 linkage, 
while avian strains prefer an α2,3 linkage. It is currently hypothesized that a switch in receptor 
specificity from avian to human preference is a key reason why influenza A viruses have crossed 
between species. Mutating only one amino acid in the HA sequence was shown to be adequate to 
make this switch. Mutations such as E190D, Q226L, and G228S were previously shown to 
induce a switch in receptor preference from avian to human in H1, H2, and H3 strains, but not in 
H5.  In this 2008 study, six amino acid mutations located outside the receptor-binding domain of 
HA were tested, including, K35R, D45N, D94N, K35R/D45N, K35R/D45N/D94N, A267T. The 
results showed that none of the mutations influenced the receptor binding, except D94N. 
Mutation D94N improved receptor binding of H5 wild type HA to human cells, and decreased 
receptor binding to avian cells.  The mutant viral titers produced by human cells were higher 
than the wild type viral titers (Su et al., 2008).  
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 Other studies found that other amino acid residues were also important.  Mutations 
S220T, D239G/N, A156T, D185N, Q226L, S227N, G228S, and K58I were found to hinder viral 
infection (Ayora-Talavera et al., 2009; Morlighem et al., 2011; Krenn et al., 2011).  In this MQP 
project, mutations were performed in both HA1 and HA2 to identify important residues in both.  
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PROJECT PURPOSE 
 
 Influenza virus infects 5-20% of the United States population annually, and is responsible 
for 3,000-49,000 fatalities.  Influenza strain H5N1 is a highly pathogenic avian influenza strain 
that currently rarely transmits to humans, but when it does, the mortality rate is usually high. The 
types of residues important for H5-type HA function are likely different than HA domains 
previously characterized for other strains (Su et al., 2008).  The specific purpose of this MQP 
project was to investigate the effects of mutations in the H5 HA gene. The infectivity of the 
mutants was compared to that of the viruses with wild type HA to help map regions of the HA 
that are important for its function.  
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METHODS 
 
Cell Maintenance  
 Two cell lines permissive for influenza infection were used throughout this project. A 
human embryonic kidney cell line (293FT) was used to generate pseudotype influenza virus 
(HIV/HA(H5)), and a human lung cancer cell line (A549) was used to determine the infectivity 
of the pseudotype viruses. Both cell lines were obtained from ATCC.  Each cell line was grown 
and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Mediatech, Inc.) and 
supplemented with 10% heat inactivated fetal bovine serum (FBS) (Gibco). The DMEM used to 
maintain the 293FT cells was also supplemented with 1% L-glutamine (200 mM solution) and 
1% MEM Nonessential Amino Acids (100X solution) (Mediatech, Inc.).  
Cells were split every 2-3 days when they reached approximately 90% confluence.  
Splitting was performed by removing the medium, washing the flask with 10 mL of 1X 
phosphate buffer saline (PBS) (Mediatech, Inc.) and adding 1 mL of 0.25% trypsin (Mediatech, 
Inc.).  Once the cells became detached from the flask, they were passaged into a new T-75 flask 
at a ratio of about 1:5 cells to fresh media. Cells were not used for experiments until they reached 
passage 3.  Cells were grown in a 37ºC incubator with 5% carbon dioxide.  
 
Mutagenized HA Plasmids  
 A small mass of each plasmid encoding wild-type or mutagenized H5-type HA protein 
constructs, and pNL4.3 encoding the HIV backbone and luciferase reporter gene, were obtained 
from Dr. Lijun Rong (University of Illinois, Chicago) and Debra Mills, a technician at 
Microbiotix. These plasmids were transformed into E. coli to produce sufficient quantities for 
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use throughout this project. 1 µL of plasmid DNA solution was added to a 50 µL vial of 
competent DH5α E. coli (Invitrogen Inc.) on ice. The vial was incubated on ice for 30 minutes to 
allow the DNA to coat the surface of the cells. After the 30 minute incubation, the vial was 
transferred to a 42ºC water bath for 30 seconds to heat-shock them and allow the DNA to be 
taken into the cells, and then placed immediately back on the ice for 2 minutes. After the 2 
minute incubation on ice, 500 µL of room temperature S.O.C. Medium (Invitrogen Inc.) was 
added to the vial, then the vial was vortexed and taped horizontally to a shaker platform at 37ºC. 
The vial was left to shake at ~300 rpm for 1 hour. Once the 1 hour of shaking was complete, the 
vial was transferred to a sterile 250 mL flask containing 100 mL of LB Miller Broth and 100 
µg/mL of Ampicillin. The flask was placed in a shaker at 37ºC overnight.  
Following the overnight incubation, the flask was removed, and plasmid DNA was 
isolated from the cells using the PureLink HiPure Plasmid Filter Midiprep Kit (Invitrogen Inc.). 
The cell suspension left overnight was poured into a 50mL conical tube and spun down at 4,000 
x g for 10 minutes to pellet the cells. The supernatant was poured off, and the cells were 
resuspended in 10 mL of lysis buffer until homogenous. Next, 10 mL of precipitation buffer was 
added to the lysate and inverted to gently mix. This mixture was poured into the HiPure Filter 
Midi Column and left to filter through the column by gravity flow. Once all the liquid had passed 
through the column, 20 mL of wash buffer was added to the column to help remove any 
unwanted particles. The wash buffer was also left to filter through the column by gravity flow. 
Upon completion, a sterile 15mL centrifuge tube was placed under the filter column and 5 mL of 
elution buffer was added to the column to elute the plasmid through the column and into the 
tube. Once the solution had drained into the tube, 3.5 mL of isopropanol was added and the tube 
was centrifuged to pellet the plasmids at 15,000 x g for 30 minutes at 4°C. After 30 minutes, the 
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supernatant was removed, and 3 mL of ethanol was added to the tube. The tube was centrifuged 
again at 15,000 x g for 15 minutes. After the 15 minute centrifugation, the supernatant was 
discarded, and the pellet was left to air dry for about 10 minutes. After drying, the pellet was 
resuspended in 100 µL of 10 mM Tris-Cl, pH 8.5, and the optical density was taken using a 
spectrophotometer.   
Upon completion of the plasmid prep, the plasmids were digested using KpnI HF and 
BamHI-HF (New England Biolabs) and run on an agarose electrophoresis gel to confirm the 
presence of the HA gene. When run on a gel, the vector (pcDNA3.1) showed a DNA band at 5 
kb, and the HA insert showed a DNA band at 1.7 kb.   
 To verify the WT or mutant HA genotype, the plasmids were sent for sequencing at 
Sequegen, Inc. in Worcester, MA. Once verified, the plasmids were used to produce pseudotype 
virus.  
 
Generation of Pseudotype Viruses 
 Pseudotype virus was generated by co-transfecting 293FT cells with plasmids encoding 
WT or mutant H5-type HA proteins and plasmid pNL4.3 R-E Luc+.  pNL4.3 R-E Luc+ encodes 
for the  HIV backbone and contains the luciferase reporter gene. 293FT cells were plated in 10-
cm petri dishes which were coated with 10 mL of a solution of 1X PBS containing 0.001% 
solution Poly L-Lysine (Sigma-Aldrich) to help cells adhere to the plates.  The plates were 
incubated at room temperature for about 30 minutes to allow Lysine attachment.  T-75 flasks 
containing confluent 293FT cells were trypsinized, and the cells were suspended in 12 mL of 
media. 1.5 mL of the cell suspension was added to each 10-cm petri dish along with 12 mL of 
media 24 hours prior to transfection.   
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 After 24 hours of cell growth, the 293FT cells were co-transfected with pNL4.3 Luc+R-E 
and either the wild type H5 HA construct or the mutant H5 HA construct. The transfection was 
as follows: For each 10-cm petri dish, 1.5 mL of Opti-MEM I (Reduced Serum Media 1X) 
(Invitrogen, Inc.) was added to a sterile 15 mL conical tube.  90 µL of Mirus transfection reagent 
(Mirusbio, Inc.) was added to the tube and gently mixed. After mixing, 7.5 µg of pNL4.3 
Luc+R-E- and 7.5 µg of the H5 HA construct (wild type or mutant) were added to the tube and 
mixed gently.  The mixture was incubated at room temperature for about 30 minutes. During the 
30 minute incubation period, the 10-cm plate, containing the 293FT cells, was removed from the 
incubator and the medium was removed from it. 10 mL of 1x PBS was used to wash the plate, 
then it was removed. 15.5 mL of DMEM (containing Glutamine, NEAA, and 3% FBS) was 
added to the dish.  After the 30 minute incubation of the conical tubes, the 1.5 mL of transfected 
cell suspension was added to the 10-cm dish, and the dish was returned to the incubator for 24 
hours. After 24 hours of incubation, the medium was removed from the 10-cm petri dish and 
replaced with 15 mL of fresh DMEM (containing 2% Glutamine, 1% NEAA, 3% FBS, 10mM 
Hepes (Thermo Scientific), 10 mM CaCl2, and 35 uL (5 units) of Neuraminidase (Sigma-
Aldrich). Neuraminidase is added externally to the cells because it is not already provided in the 
pseudotype system and is essential for infection. After another 24 hours of incubation, the virus 
was harvested by centrifugation to pellet any cells, and the supernatant containing virus was 
poured into sterile conical tubes. The virus was stored at 4ºC until use.  
 
Test of Viral Infection 
After the wild type and mutant H5 pseudotype viruses were prepared, they were tested 
for infectivity in A549 cells by doing a pseudotype virus infection assay. 24 hours prior to 
infections, A549 cells were plated in 96-well CulturPlates (Perkin-Elmer) at a concentration of 
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4x10
4
 cells/mL in complete medium. The 96-well plates were then incubated at 37ºC in 5% CO2.  
After 24 hours of incubation, a separate 96-well plate was used to do a 1:5 dilution of virus in 
media (containing no FBS) from rows A to H. Each virus dilution was performed in duplicate.  
The 1:5 dilution was used to ensure that the undiluted reading of the plate was not above the 
linear range of the luminometer when assaying for Luciferase activity. The medium was 
removed from columns 2-11 of the 96-well plate containing cells. Medium was not removed 
from columns 1 and 12, and virus was never added to these columns. Columns 1 and 12 were 
used as background for the assay and represented the negative control “no infection”. 100 µL of 
the dilutions made in the other 96-well plate were transferred to the plate containing A549 cells. 
After the virus was added to the 96-well plate, the plate was returned to the incubator for 5 hours. 
After 5 hours, the medium was removed from the plate and replaced with 100 µL/well of fresh 
DMEM (without phenol red, containing 2% Glutamine, 1% NEAA, 10% FBS) (Mediatech, Inc.). 
The plate was then returned to the incubator and left for 72 hours. After 72 hours, the plates were 
removed from the incubator, and 100 µL of BriteLite Plus (ultra-high sensitivity luminescence 
reporter gene assay system) containing substrate solution (Perkin-Elmer) was added to each well. 
Plates were sealed and left to shake at room temperature for about 5 minutes. A reading of 
luminescence was done by putting plates in an EnVision plate reader (2102 Multilabel Reader) 
(Perkin Elmer). 
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RESULTS 
 
 Influenza virus infects 5-20% of the United States population annually and causes 
thousands of fatalities. The influenza strain H5N1 is a highly pathogenic avian strain that is 
currently not transmitted to humans. The fear is that if this strain is able to transmit to humans, it 
will result in a worldwide pandemic. An essential structure of the virus involved in infection of 
the host cells is the envelop glycoprotein, hemagglutinin (HA). Although previous experiments 
(discussed in Background) have characterized several HA domains important for function in a 
variety of influenza strains, little is known about H5N1 type HA. During this project, a series of 
point mutations in the H5 HA gene were tested for their infectivity compared to the wild type H5 
HA to identify domains important for HA function.  
 Table 1 shows a list of all the mutants tested in this project in numerical order. The first 
column shows the mutant tested, the second column shows the region of the HA that the mutant 
is found, and the third column describes the mutant infectivity relative to WT.  As shown, 65 of 
the 70 mutants tested reside in the H5 HA1 region, while 5 reside in the HA2 region.  Of the 70 
mutants tested, 25 showed infectivity levels similar to the WT, 24 showed no infectivity, 18 
showed decreased infectivity, and 3 showed increased infectivity.  Figure 5 shows the 
crystalline, monomeric structure of H5 HA denoting the mapped mutants of interest. All of the 
mutants in Table 1 that showed higher, lower, or no infectivity compared to the wild type are 
mapped on this figure. Not shown are the mutants that had no effect on infectivity. The mutant 
D199A is shown in green as if it had higher infectivity than the wild type. This mutant did show 
slightly higher infectivity than the wild type, however, not significantly higher. As shown in the 
figure, the majority of the mutants showing no infectivity are located within the group specific 
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pocket and the stem region on the HA monomer. The mutants that showed decreased infectivity 
are located in the stem as well as in the beta-sheets of the head. The mutants showing increased 
infectivity are located in the head of the HA, as well as close to the group specific pocket. The 
mutant K64A is actually located within the group specific pocket.  
 
Table 1: Complete List of Mutants Tested 
 
Mutant  
Region 
of HA 
% Infectivity 
Compared to 
 Wild Type 
E30A HA1 Similar 
M36A HA1 no infectivity 
E37A HA1 Lower 
K38A HA1 Lower 
H44A  HA1 Similar  
D47A HA1 Lower 
I48A HA1 no infectivity 
L49A HA1 no infectivity 
E50A HA1 Similar 
K51A HA1 Lower 
K52A HA1 Similar 
H53A HA1 Similar 
N54A HA1 no infectivity 
G55A HA1 no infectivity 
K56A HA1 Lower 
L57A HA1 Lower 
C58A HA1 no infectivity 
D59A HA1 Similar 
D61A HA1 Similar 
G62A HA1 Lower 
V63A HA1 Lower 
K64A HA1 Higher 
P65A HA1 no infectivity 
L66A HA1 Lower 
I67A HA1 Lower 
L68A HA1 no infectivity 
D84A HA1 Similar 
E85A HA1 Similar 
E115A HA1 Similar 
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E115S HA1 no infectivity 
R123A HA1 no infectivity 
R123E HA1 no infectivity 
H126A HA1 no infectivity 
H126R HA1 Lower 
E128A HA1 Lower 
K129A HA1 Similar 
K135A HA1 Lower 
W138A HA1 Lower 
E142A HA1 Similar 
K156A HA1 Similar 
F159A HA1 Lower 
F160A HA1 Lower 
R161A HA1 Lower 
K168A HA1 Similar 
K169A HA1 Similar 
Y173A HA1 Similar 
N182A HA1 no infectivity 
E186A HA1 Lower 
D187A HA1 no infectivity 
D199A HA1 Similar 
E202D HA1 no infectivity 
K205A HA1 Similar 
Q223E HA1 Similar 
Q223L HA1 Similar 
K234A HA1 Higher 
K250A HA1 Similar 
D253A HA1 no infectivity 
D253E HA1 Similar 
D253K HA1 no infectivity 
E284A HA1 Similar 
E286A HA1 Similar 
K293A HA1 no infectivity 
E317A HA1 no infectivity 
K320A HA1 no infectivity 
R326A HA1 Similar 
R421A HA2 Higher 
R421G HA2 No infectivity 
L426A HA2 no infectivity 
F434K HA2 no infectivity 
F456A HA2 no infectivity 
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Figure 5:  Structure of the H5 HA Monomer Showing  
the Positions of Mapped Mutants of Interest. 
 
Mutants with Higher Infectivity 
Figure 6 shows a summary of all three mutants displaying higher infectivity than WT.  
Mutants K64A and K234A all reside in the HA1 region, while R421A resides in the HA2 region, 
near the group specific pocket. The mutant K64A is located in the group specific pocket.  
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Figure 6: HA Mutations Showing Higher Infectivity Compared to Wild Type. 
 
Mutants with Decreased Infectivity  
 Figure 7 shows a graph of all the mutants tested that showed infectivity that was less 
than the wild type.  
 
Figure 7: HA Mutations Showing Less Infectivity Compared to Wild Type. 
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Mutants with no Infectivity 
 Table 2 shows a chart of the mutations showing no detectable infectivity compared to the 
wild type.  In these cases, the single amino acid mutation shown resulted in pseudotype virus that 
was no longer infectious to permissive cells.  
Table 2:  Mutants Showing No Infectivity Relative to Wild Type. 
Mutant % Infectivity of Wild Type 
WT 100 
M36A 0.00 
I48A 0.09 
L49A 0.00 
N54A 0.03 
G55A 0.01 
C58A 0.00 
P65A 0.68 
L68A 0.00 
E115S 0.47 
R123A 0.00 
R123E 0.16 
H126A 0.04 
N182A 0.00 
D187A 0.01 
E202D 0.21 
D253A 0.01 
D253K 0.05 
K293A 0.16 
E317A 0.02 
K320A 0.05 
R421G 0.10 
L426A 0.00 
F434K 0.08 
F456A 0.00 
 
Group Specific Pocket Region  
Figure 8 shows the infectivity for a subset of the mutants tested in the group specific 
pocket region of HA at amino acids 50-70. This domain is important because it differs depending 
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on the influenza type, and divides HA into two separate groups. Of the 17 mutants tested in this 
domain, 6 showed decreased infectivity, 9 showed no infectivity, 1 showed infectivity equal to 
WT, and 1 (K64A) showed higher infectivity.   
 
Figure 8: Summary of Infectivity for H5 HA Domain 50-70. 
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DISCUSSION 
 
One of the main reasons strain H5N1 was studied throughout this project is because it is a 
highly pathogenic avian influenza strain. Although this influenza strain is rarely transmitted to 
humans, it is feared that, if this occurs, a worldwide pandemic will result. This study was 
performed to identify amino acids that are important for HA (H5) function. HA is an envelope 
glycoprotein present on the surface of the influenza virus. HA plays an essential role in infection 
of target host cells by recognition and binding of the virus to the host cell receptors. The 
pseudotype influenza strain H5N1 was used throughout this project. Little is known about H5N1 
HA except that the key residues are likely different than previously characterized strains (Su et 
al., 2008).  In this project, a series of 70 point mutations in the H5 HA protein were tested in 
pseudotype viruses against permissive A549 cells, a human lung cancer cell line. The infectivity 
of these mutants was compared to the infectivity of the wild type H5N1 pseudotype virus in 
order to identify domains important for H5 HA function. An important region in the HA gene 
resides between amino acids 50-70 and is called a group specific pocket. This domain differs 
between influenza types and divides HA into two separate groups (group 1 includes H1 and H5, 
while group 2 includes H3 and H7).  
 The results show that of the 70 HA mutants tested, 25 showed infectivity levels similar to 
the WT, 24 showed no infectivity, 18 showed decreased infectivity, and 3 showed increased 
infectivity.  The fact that a large number of mutants showed either no infectivity, lower 
infectivity, or higher infectivity implies those residues are important for HA function and viral 
infection. The crystal structure of monomeric H5 HA displays a map of all the mutants that 
resulted in higher, lower, and no infectivity compared to the wild type (Figure 5). As shown in 
the figure, most of the mutants that resulted in no infectivity are located in the stem region of the 
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structure. The mutants showing decreased infectivity are also located mostly in the stem region, 
as well as in the beta-sheets of the head region. Since mutants in these regions result in no 
infectivity or a decrease in infectivity, they are essential for HA function and viral infection. 
Mutants that resulted in increased infectivity are mostly located in the head region of HA 
(D199A, K156A, and K234A). Although the mutant D199A does not show a significant increase 
in infection compared to the wild type, it is still located in the head region. The other mutants 
that showed increased infectivity are located near (R421A) and within (K64A) the group specific 
pocket. These results indicate that mutants in the head and group specific pocket regions are both 
important for infectivity and are potential areas for mutations that could result in pandemics, 
since they enhance infectivity in human cells.  
 The group specific pocket differs in the region 50-70. Based on the 3D crystal structure 
of HA, it appears to be extremely important because the majority of mutants tested from this 
region resulted in no infectivity or decreased infectivity. The only mutant in this domain that 
resulted in higher infectivity compared to the wild type is K64A. This amino acid is usually a 
polar lysine, however, it was mutated to be a non-polar alanine. Since the switch from a lysine to 
an alanine resulted in an increase in infectivity, this shows that the non-polar amino acid actually 
aids in infection.  Only five of the mutants tested in this region (E50A, K52A, H53A, D59A, and 
D61A) had no significant impact on infectivity. From these results, it is suggested that antivirals 
made to target the group specific pocket would be successful because it is an important region 
for infection.  
Jean-Etienne Morlighem and her team previously tested mutation A156T in the H1N1 
influenza strain, collected in Japan during the 2009 pandemic and resulted in severe cases of 
infection.  Her results showed that this mutation is located in the Ca antigenic site, rather than the 
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receptor-binding site (Morlighem et al., 2011).  In this MQP study, the mutation K156A in the 
H5N1 influenza strain was tested. Unlike Morlighem’s results, this mutant showed infectivity 
that was about equal to that of the wild type. Morlighem’s results showed increased infectivity. 
The discrepancy in results could be due to the fact that the influenza strains are different. 
 Overall, this research project went smoothly. One small problem was encountered during 
mutant sequencing.  Some of the mutants did not sequence properly and could not be read, while 
other mutants contained the expected mutation but also contained an additional mutation. These 
mutants were not used in infection experiments. Amino acids 50-70 were expected to be 
important in HA function based on HA analyses in other strains, and we hoped to be able to test 
all of these mutants, but three of the mutant clones within this region were not able to be made 
due to errors with the PCR primers; so unfortunately mutants were not tested for amino acids 60, 
69, or 70.  
 In the future, amino acids 60, 69, and 70 should also be tested to create a complete 
picture of this region and to make more definitive conclusions. Due to time constraints, not all 
amino acids in the HA protein were mutated. The remaining mutants should be made and tested 
for their infectivity compared to the wild type H5 HA and to other HA strains. Most of the 
mutants that were created in this project were mutated to an alanine, which is a hydrophilic, 
neutral amino acid.  It would be interesting to also make mutations that are hydrophobic or 
charged to see how their infectivity compares.  
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